AmCad BioMed Corporation announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 14.460 million compared to TWD 16.276 million a year ago. Operating loss was TWD 16.310 million compared to TWD 17.171 million a year ago. Net loss was TWD 9.864 million compared to TWD 12.027 million a year ago. Basic loss per share was TWD 0.19 compared to TWD 0.23 a year ago. For the nine months, sales was TWD 43.928 million compared to TWD 69.982 million a year ago. Operating loss was TWD 46.914 million compared to TWD 31.953 million a year ago. Net loss was TWD 31.149 million compared to TWD 19.605 million a year ago. Basic loss per share was TWD 0.59 compared to TWD 0.37 a year ago.